Kodiak Hub CEO Malin Schmidt Nominated for SaaSiest CEO of the Year
6.5.2025 11:00:00 CEST | Business Wire | Press Release
Kodiak Hub, an AI-powered supplier relationship management (SRM) platform, today announced that CEO Malin Schmidt is nominated for SaaSiest CEO of the Year, a peer-voted honor spotlighting the most visionary and impactful leaders in European Software as a Service (SaaS).
Schmidt is one of four finalists selected by the SaaSiest CEO Network, an invite-only community of SaaS leaders across the European region. The award celebrates founders and executives who’ve scaled high-growth businesses while contributing meaningfully to the broader SaaS ecosystem.
As CEO of Kodiak Hub, Schmidt is redefining SRM—a space long dominated by legacy suites—with an AI-powered platform that helps companies make faster, smarter decisions so they can drive performance, consistency and real-world impact. Under her leadership, Kodiak has expanded into the U.S. market with $12 million in funding, fueling the company’s expansion and growth across its manufacturing, industrial and food & beverage customer base.
“We built Kodiak Hub to help businesses navigate global supply chains, enabling smarter buying decisions in a very turbulent global trade landscape,” said Malin Schmidt, CEO of Kodiak Hub. “Being named alongside Europe’s top SaaS leaders validates the impact we’re making and pushes us to keep raising the bar on how companies stay competitive in their markets and drive top-line growth.”
Kodiak Hub uses AI and automation to help procurement teams make sense of scattered supplier data, automate tasks like intake and qualification, track performance in real time and provide clear recommendations to reduce risk and move faster.
The winner will be announced live on May 6th at SaaSiest 2025 in Malmö, Sweden. As part of the event, Schmidt will lead a keynote session onstage titled: “The CEO´s Guide to Cracking the Enterprise Code”.
For more information about the SaaSiest and Malin Schmidt’s keynote, visit www.saasiest2025.com
About Kodiak Hub
Kodiak Hub, founded in 2016, operating across Europe & Headquartered in Stockholm, Sweden, is a provider of a cloud-based Supplier Relationship Management (SRM) SaaS empowering global procurement teams to source smarter - powering sustainable supplier relationships.
Kodiak Hub offers a modular suite of SRM solutions that teams can plug n’ play and an end-to-end platform that enables buyers, category managers, and procurement teams to drive operational, tactical and strategic business value. With features like automated supplier intake and qualification, performance monitoring, and management, and buyer-supplier innovation, Kodiak Hub transforms how teams manage supplier relationships. Teams that use Kodiak Hub power Performance, Predictability, and Purpose in global supply chains.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506754396/en/
Contacts
Media Contact
Corporate Ink for Kodiak Hub
kodiakhub@corporateink.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom